齐拉西酮与氟哌啶醇治疗首发精神分裂症对照研究

目的评价齐拉西酮治疗精神分裂症的疗效及安全性。方法对72例精神分裂症患者随机分为研究组和对照组．每组各36例。研究组应用齐拉西酮治疗，起始20mg／d．最大剂量≥120mg／d。对照组以氟哌啶醇治疗。起始剂量12mg／d，最大剂量≥52mg／d。病程均为8周。疗效指标包括阳性和阴性症状量表（PANSS）；不良反应指标为不良反应量表（TESS）及有关实验室检查。结果齐拉西酮组有效率为94．4％，氟哌啶醇组有效率为91．6％；两组疗效差异无显著性。不良反应的发生率两组间比较差异无显著性，但心电图的异常率氟哌啶醇组明显高于齐拉西酮组，两组之间比较有显著性差异（P〈0．05）。结论齐拉西酮是一种安全、有效的非典型抗精神病药物。

Contrast Study of Ziprasidone Versus Haloperidol in the Treatment of First-episod Schizophrenia

Objective To explore the curative effects and safety ziprasidone in the treatment of first-episod schizophrenia. Methods 72 schizophrenics were randomly divided into research （Ziprasidone, n= 36） and controlled （Haloperidol, n= 36）. Initial dosage of ziprasidone was 20mg/d, the maximal was ≥120mg/d; Initial dosage of Haloperidol was 12mg/d, the maximal was 52mg/d for 8 weeks. The PANSS, TESS and related lab tests were employed for assessing the treatment effectiveness and side effects. Results The rates were 94.4% in ziprasidone group and 91.6% in haloperidol group, which was no significant difference between two groups. However, in the item of the influence to EEG, patients in ziprasidone group reported much fewer side effects than those in haloperidol group（P〈0.05）. Conclusion The study suggests that Ziprasidone is a safe and effective agent in the treatment of schizophrenia.